Reported 1 day ago
Novo Nordisk's stock has gained 2.1% after a Financial Times report highlighted successful weight loss results from new trials of higher doses of Ozempic, showing an average weight loss of 19% compared to 16% at lower doses. Although Eli Lilly's Mounjaro shows slightly better results, Novo's product remains competitive, and analysts note its lower price-to-earnings ratio and higher dividend yield make it an attractive option despite potential risks from pricing strategies.
Source: YAHOO